Frontage Doubles Bioanalytical Lab Capacity
Frontage Appoints Dr. Michael S. Willett as President of Clinical Services
Exton, PA – September 8, 2015 – Frontage, a full service contract research organization (CRO), today announced the appointment of Michael S. Willett, PharmD., RAC as President of its clinical business unit.
Frontage Expands Clinical Operations in Secaucus, NJ
Exton, PA – May 5, 2015 – Frontage, a full service contract research organization (CRO), today announced the opening of its newest facility in Secaucus, NJ to expand its clinical research portfolio of services.
Frontage Laboratories Awarded GROW New Jersey Grant for Clinical Operations Expansion
Exton, P.A. – September 9, 2014 – Frontage Labs has received a grant award of $2.44m from the New Jersey Economic Development Authority. As part of Grow New Jersey Assistance Program, the incentive grant will be used for construction and capital investments involving a 36,000 square foot facility in Secaucus, NJ; to support Phase I-III clinical research.
Frontage Laboratories Recognized as “Fastest Growing Company” by INC Magazine
Exton, P.A. – August 22, 2014 – Frontage today announced recognition by INC Magazine in the INC 5000. For the second time in three years, Frontage earned a spot on the magazine’s thirty-third annual compilation of America’s fastest-growing privately-held companies. Qualifying organizations must demonstrate consistent year-on-year revenue growth and future potential success. In the past three years, the company has achieved nearly 50% revenue growth and added close to 100 new positions. Among companies listed in the greater Philadelphia area, Frontage ranked sixteenth position for new jobs creation.
Tigermed and Frontage Laboratories Complete Strategic Investment Agreement
Exton, P.A., (July 30, 2014) – Hangzhou Tigermed Consulting Co., Ltd. and Frontage Laboratories, Inc. today announced completion of the previously announced investment agreement, following approval by the China Securities and Regulatory Commission. Tigermed, a leading provider of outsourced clinical development services across China and Asia Pacific regions to the pharmaceutical and medical device industries has acquired a majority position in the ownership of Frontage, a recognized leader in bioanalysis, preclinical studies, early phase clinical studies and product development services for biopharmaceutical organizations.